Evidence map›Paper›PMID 29716623›Full record

ArticleJournal of experimental & clinical cancer research : CR2018

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.

Maria Francesca Santolla, Rosamaria Lappano, Francesca Cirillo, Damiano Cosimo Rigiracciolo, Anna Sebastiani, Sergio Abonante, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Teresa Di Martino, Marcello Maggiolini and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04811898 (A Dose Escalation Phase I Study of LNA-i-miR-221 for the Treatment of Refractory Multiple Myeloma and Advanced Solid Tumors), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04811898 phase1completednot on this mapstarted 2019, after this paper: background citation

A Dose Escalation Phase I Study of LNA-i-miR-221 for the Treatment of Refractory Multiple Myeloma and Advanced Solid Tumors

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Mater Domini, CatanzaroRan2019 to 2021Enrolled17ConditionsMultiple Myeloma, Refractory, Hepatocarcinoma, Advanced Solid TumorArmsLNA-i-miR-221
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. NF-κB in inflammation and cancer.Cellular & molecular immunology · 2025
    Review
  6. MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications.Journal of experimental & clinical cancer research : CR · 2025
    Review
  7. Article
  8. Article
  9. TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma.Journal of experimental & clinical cancer research : CR · 2023
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. GPER1 and microRNA: Two Players in Breast Cancer Progression.International journal of molecular sciences · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Maria Francesca SantollaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Rosamaria LappanoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Francesca CirilloDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Damiano Cosimo RigiraccioloDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Anna SebastianiDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Sergio AbonanteRegional Hospital Cosenza, Cosenza, Italy.
Pierfrancesco TassoneDepartment of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy.
Pierosandro TagliaferriDepartment of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy.
Maria Teresa Di MartinoDepartment of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy. teresadm@unicz.it.
Marcello MaggioliniDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy. marcellomaggiolini@yahoo.it.
Adele VivacquaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
University of Calabria · ITMagna Graecia University · ITAzienda Ospedaliera di Cosenza · IT

Funding

Associazione Italiana per la Ricerca sul Cancro 16719/2015Associazione Italiana per la Ricerca sul Cancro 9980/2010-2015
6 · The paper itself

Abstract

backgroundMicroRNA (miRNAs) are non-coding small RNA molecules that regulate gene expression by inhibiting the translation of target mRNAs. Among several dysregulated miRNAs in human cancer, the up-regulation of miR-221 has been associated with development of a variety of hematologic and solid malignancies. In this study, we investigated the involvement of miR-221 in breast cancer.

methodsTaqMan microRNA assay was used to detect the miR-221 levels in normal cells and in MDA-MB 231 and SkBr3 breast cancer cells as well as in main players of the tumor microenvironment, namely cancer-associated fibroblasts (CAFs). miR-221 mimic sequence and locked nucleic acid (LNA)-i-miR-221 construct were used to induce or inhibit, respectively, the miR-221 expression in cells used. Quantitative PCR and western blotting analysis were performed to evaluate the levels of the miR-221 target gene A20 (TNFAIP3), as well as the member of the NF-kB complex namely c-Rel and the connective tissue growth factor (CTGF). Chromatin immunoprecipitation (ChIP) assay was performed to ascertain the recruitment of c-Rel to the CTFG promoter. Finally, the cell growth and migration in the presence of LNA-i-miR-221 or silencing c-Rel and CTGF by specific short hairpin were assessed by cell count, colony formation and boyden chambers assays. Statistical analysis was performed by ANOVA.

resultsWe first demonstrated that LNA-i-miR-221 inhibits both endogenous and ectopic expression of miR-221 in our experimental models. Next, we found that the A20 down-regulation, as well as the up-regulation of c-Rel induced by miR-221 were no longer evident using LNA-i-miR-221. Moreover, we established that the miR-221 dependent recruitment of c-Rel to the NF-kB binding site located within the CTGF promoter region is prevented by using LNA-i-miR-221. Furthermore, we determined that the up-regulation of CTGF mRNA and protein levels by miR-221 is no longer evident using LNA-i-miR221 and silencing c-Rel. Finally, we assessed that cell growth and migration induced by miR-221 in MDA-MB 231 and SkBr3 breast cancer cells as well as in CAFs are abolished by LNAi-miR-221 and silencing c-Rel or CTGF.

conclusionsOverall, these data provide novel insights into the stimulatory action of miR-221 in breast cancer cells and CAFs, suggesting that its inhibition may be considered toward targeted therapeutic approaches in breast cancer patients.

Indexed as

Breast NeoplasmsCell Line, TumorConnective Tissue Growth FactorFemaleFibroblastsHumansMicroRNAsSignal TransductionTransfectionConnective Tissue Growth FactorMicroRNAsMIR221, humanA20Breast cancerCAFsC-RelCTGFmiR-221

Identifiers

PMID29716623
PMCPMC5930435
OpenAlexW2805949429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.